D. Boral Capital Reaffirms "Buy" Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $5.00 price target on the stock.

VNRX has been the subject of several other reports. StockNews.com initiated coverage on VolitionRx in a research note on Tuesday. They issued a "sell" rating for the company. Benchmark restated a "hold" rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Trading Down 4.5 %

NYSE VNRX traded down $0.03 on Wednesday, hitting $0.63. 98,210 shares of the company were exchanged, compared to its average volume of 97,862. The company has a market cap of $58.38 million, a PE ratio of -1.75 and a beta of 1.20. The stock has a fifty day moving average of $0.65 and a 200-day moving average of $0.66. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.23.

Insider Buying and Selling

In other news, CEO Cameron John Reynolds acquired 139,811 shares of the business's stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares of the company's stock, valued at $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Guy Archibald Innes bought 174,764 shares of the stock in a transaction dated Monday, December 9th. The stock was purchased at an average price of $0.57 per share, with a total value of $99,615.48. Following the acquisition, the director now owns 617,085 shares of the company's stock, valued at $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 358,266 shares of company stock worth $204,212 in the last quarter. Insiders own 12.80% of the company's stock.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its stake in VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 45,959 shares of the company's stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 as of its most recent filing with the SEC. 8.09% of the stock is currently owned by institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.